CN111184854A - Chinese medicinal prescription for preventing virus infection - Google Patents
Chinese medicinal prescription for preventing virus infection Download PDFInfo
- Publication number
- CN111184854A CN111184854A CN202010117903.3A CN202010117903A CN111184854A CN 111184854 A CN111184854 A CN 111184854A CN 202010117903 A CN202010117903 A CN 202010117903A CN 111184854 A CN111184854 A CN 111184854A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicine
- chinese medicinal
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000009385 viral infection Effects 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 42
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 10
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 8
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 8
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 8
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 6
- 235000006533 astragalus Nutrition 0.000 claims abstract description 6
- 235000008397 ginger Nutrition 0.000 claims abstract description 6
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 4
- 244000273928 Zingiber officinale Species 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 27
- 239000008187 granular material Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims 8
- 208000036142 Viral infection Diseases 0.000 claims 4
- 239000007963 capsule composition Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 230000001717 pathogenic effect Effects 0.000 abstract description 16
- 238000005728 strengthening Methods 0.000 abstract description 6
- 244000052769 pathogen Species 0.000 abstract description 5
- 241000712461 unidentified influenza virus Species 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 229940107666 astragalus root Drugs 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 4
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 241000234314 Zingiber Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 102000048657 human ACE2 Human genes 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001061264 Astragalus Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine prescription for preventing virus infection, which consists of the following traditional Chinese medicines in parts by weight: 20 parts of astragalus membranaceus, 5 parts of honeysuckle, 5 parts of platycodon grandiflorum, 6 parts of dried orange peel and 2 parts of dried ginger. The traditional Chinese medicine formula disclosed by the invention has the advantages that the selected medicinal materials are compatible, the traditional Chinese medicine formula accords with the theories of traditional Chinese medicine and modern medicine, the traditional Chinese medicine is adopted as the raw materials, the curative effect is definite, the price is low, no toxic or side effect exists, the traditional Chinese medicine formula has the functions of strengthening the body resistance and consolidating the exterior, and eliminating turbid pathogen and detoxifying, and is used for preventing influenza virus and coronavirus infection.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine prescription for preventing virus infection.
Background
The TCM is considered to be a natural product of nature and generated by the essence of nature, and is made according to the four-hour method. The human body is also composed of qi, which is the most basic substance constituting the human body and also the most basic substance for maintaining the life activities of the human body. In traditional Chinese medicine, healthy qi represents the disease resistance of human body, pathogenic qi marks all pathogenic factors, and healthy qi fails to resist the invasion of pathogenic qi to explain the disease. If the body is vigorous, pathogenic qi will not invade easily, or even if there is pathogenic qi invasion, the disease will not be caused, only if the body's vital qi is relatively deficient, the pathogenic qi can invade by deficiency. The earliest classic book of traditional Chinese medicine, Huangdi's internal classic, has a discussion of the existence of healthy qi and the failure of pathogenic factors to dry.
The traditional Chinese medicine plays an important role in preventing and controlling epidemic situations regardless of ancient typhoid fever, pestilence and epidemic diseases such as current SARS. Aiming at the pneumonia epidemic situation infected by the current novel coronavirus, the characteristic advantages of the traditional Chinese medicine are fully exerted, and the prevention before illness is necessary. The people with pneumonia infected by the novel coronavirus generally have the characteristics of susceptibility, deficiency of vital qi, excess pathogenic factors, mixed cold and heat and the like, and have the advantages of acute onset, strong infectivity, high incidence and long course of disease. Therefore, the research and development of products for preventing the infection of the influenza virus and the coronavirus, which have obvious curative effect, can enhance the immunity of human bodies, resist viruses and have low toxic and side effects, have important significance.
Disclosure of Invention
The invention mainly solves the technical problems in the prior art, thereby providing a traditional Chinese medicine prescription for preventing virus infection.
In order to achieve the purpose, the invention provides the following technical scheme:
a traditional Chinese medicine prescription for preventing virus infection is composed of the following traditional Chinese medicines in parts by weight: 20 parts of astragalus membranaceus, 5 parts of honeysuckle, 5 parts of platycodon grandiflorum, 6 parts of dried orange peel and 2 parts of dried ginger.
Preferably, the traditional Chinese medicine prescription is an oral liquid preparation.
Preferably, the traditional Chinese medicine prescription is a capsule preparation.
Preferably, the Chinese medicinal preparation is a tablet.
Preferably, the traditional Chinese medicine prescription is a medicinal granule.
The raw materials used in the invention have the following effects:
astragalus root, radix astragali, sweet in taste and warm in nature, enters spleen and lung channels, has thin and thick smell, can rise and fall, is specially used for qi system to express superficies, and is good at tonifying qi. According to pharmacological research, astragalus can enhance and regulate the immune function of an organism, resist viruses and improve the disease resistance of the organism. Zhang shan Lei recorded in Ben Cao Zheng Yi (Zheng Cao Zheng Yi) of Huang Qi, tonifying middle-jiao soil, warming and nourishing spleen and stomach, so it is most suitable for treating deficiency of middle-jiao energy, weakness of spleen soil and sinking of clear qi. It is the best remedy for diseases due to exterior deficiency because its skin directly reaches the skin surface and muscles of human body, strengthens and protects yang, and fills the exterior and interior. The original menstrual period was: 'Huang Qi can tonify deficiency of five zang organs, remove lung heat, without sweating to cause sweating, stopping sweating, entering lung to consolidate superficial deficiency and spontaneous sweating' Ben Cao gang mu Shi Yi (supplement to compendium of materia Medica): for lung deficiency, it can tonify lung qi. The "kojiu" is recorded: the main symptoms of the disease are also the main symptoms of the disease. For wind-rain and pathogenic wind, the qi must be deficient, so Huang Qi can be used to promote healthy qi. "
Honeysuckle flower is cold in nature and sweet in taste, has light and aromatic smell, enters lung, stomach and large intestine channels, has the effects of clearing heat, detoxifying and dispelling wind and heat, can clear qi and nourish yin, can clear heat in the qi system and detoxify toxin in the blood system, is mainly used for treating warm diseases due to heat permeating through the upper half body. It is said to be fragrant and sweet in the original meridian, entering spleen and dredging lung, tonifying in diarrhea. In the formula, astragalus root, radix astragali, sweet in taste and sweet in flavor, warms the spleen and tonifies middle-warmer energy, is preferred to tonify spleen qi, astragalus root is used for strengthening body resistance, and honeysuckle is used for eliminating pathogenic factors, so that the formula can be used for treating two sides of the contradiction of deficiency of body resistance and excess of pathogenic factors, and reflects the compatibility of both principal and secondary aspects.
Platycodon grandiflorum is bitter and pungent in flavor, neutral in nature, enters lung meridian, is pungent in flavor and bitter in flavor and releases its flavor, is light in weight and floating, is an agent for yellow millet, is good at ventilating lung qi, relieving exterior syndrome and relieving sore throat, eliminating phlegm and discharging pus, and has the function of guiding drugs to float upwards into the lung. The combination of the two herbs of Jie Geng and jin Yin Hua can achieve the actions of dispersing wind, clearing heat, dispersing lung qi and relieving cough. According to pharmacological research, the platycodon grandiflorum has the effects of relieving cough, clearing heat and enhancing immunity. In the book of meridian origin, ascending of qi and clearing lung qi, relieving sore throat, leading to meridian of lung. Platycodon grandiflorum is reported in the pearl sac, and is used for treating sore throat, benefiting lung qi and treating nasal obstruction. "can be either minister or envoy.
The dried orange peel is pungent, bitter and warm, enters spleen, lung, stomach and large intestine channels, mostly enters spleen, has the functions of regulating qi, strengthening spleen, eliminating dampness, eliminating turbid pathogen, regulating stomach and is a ministerial drug. The dried orange peel is pungent and opens up with bitter taste to lower, so that the qi can moisten, the spleen can invigorate the stomach, and the dried orange peel is used together with the astragalus root to supplement and disperse, the astragalus root can be used for the dried orange peel without the defect of retention of pathogens, the dried orange peel can be used for the dried orange peel without too much dispersion, and the dried orange peel can be used for both supplementing the middle and dispersing. The compendium of materia Medica records: orange peel, bitter in flavor and dry in flavor and pungent in flavor and warm in flavor, is used for treating various diseases, and has the actions of regulating qi and drying dampness, tonifying with tonics, purging with purgatives, ascending with ascending-qi herbs, descending with descending-qi herbs, spleen being mother of original qi, and lung being punt-qi-controlling herbs, so orange peel is a herb for qi in two meridians, but can be used for tonifying and purging with ascending and descending with the herbs. "the essentials of medilin" is called: the upper part of the body is used for purging pathogenic lung and descending adverse qi; dryness-dampness in the middle energizer and harmonizing the middle energizer; when it is downward, it can disperse liver qi and moisten kidney. It is mainly used for regulating qi, resolving phlegm and resolving stagnation. "
Gan Jiang is pungent and warm in property, and enters spleen, stomach, kidney, heart and lung meridians. It can warm the heart and lung, middle-jiao, spleen and stomach, and lower-jiao. The combination of the astragalus root and the astragalus root has the functions of tonifying deficiency of spleen and stomach, restoring yang of middle jiao, enabling middle-jiao to be transported and managed, warming yang among qi, tonifying qi among yang, tonifying qi when yang is obtained, transforming qi when yang is obtained, and strengthening qi, supporting yang, consolidating superficial resistance and arresting sweating. Both gan Jiang and Chen Pi are pungent and warm in flavor and warm in nature, enter spleen meridian, and they are combined together to mutually reinforce each other to take the effect of warming middle energizer and resolving turbidity. The combination of gan Jiang and jin Yin Hua can tonify spleen yang, clear excess heat, pungent flavor and bitter taste, and induce heat to disperse from middle energizer, so it is indicated for various syndromes of cold-heat combination. Honeysuckle flower and dried ginger are used as adjuvant drugs.
Through the technical scheme, the invention provides a traditional Chinese medicine prescription for preventing virus infection, which is supported by an oral liquid preparation through the proportion of five traditional Chinese medicines. The oral preparation has effects of strengthening body resistance, consolidating constitution, eliminating turbid pathogen, and removing toxic substance, and also has spleen invigorating effect. All the medicinal materials are medicinal and edible traditional Chinese medicines, are safe and reliable, and are suitable for the public to prevent the infection of influenza virus and coronavirus.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
A traditional Chinese medicine prescription for preventing virus infection is composed of the following traditional Chinese medicines in parts by weight: 20 parts of astragalus membranaceus, 5 parts of honeysuckle, 5 parts of platycodon grandiflorum, 6 parts of dried orange peel and 2 parts of dried ginger.
Preferably, the traditional Chinese medicine prescription is any one dosage form in traditional Chinese pharmacology, and can be prepared into capsule preparations, tablets, granules, oral liquid preparations, soft capsule preparations and the like.
Example 1: the traditional Chinese medicine composition is prepared into an oral liquid preparation, and 200ml of the oral liquid preparation is prepared in one bottle. The usage and dosage are as follows: it is administered orally with empty stomach in the morning and evening, with dosage of 10ml for adult (weight more than 40-50 kg) and 5ml for children (weight 15-40 kg).
Example 2: the traditional Chinese medicine composition is prepared into capsule preparation, and 3g of the capsule preparation is prepared. The usage and dosage are as follows: is administered with warm water, and is administered with empty stomach in the morning and evening, 2 granules for adult (weight of 40-50 kg) and 1 granule for children (weight of 15-40 kg).
Example 3: the traditional Chinese medicine composition is prepared into granular preparation, and 3g of the granular preparation is packaged. The usage and dosage are as follows: it is administered with warm water, and is administered with empty stomach in the morning and evening, 2 bags for adult (weight above 40-50 kg) and 1 bag for children (weight 15-40 kg).
Example 4A tablet of the Chinese medicinal composition of the present invention is prepared, one tablet being 1 g. The usage and dosage are as follows: is administered with warm water, and is administered with empty stomach in the morning and evening, 2 tablets for adult (weight of 40-50 kg) and 1 tablet for children (weight of 15-40 kg).
Clinical cases:
the therapeutic effects of the Chinese medicinal compositions of examples 1 to 4 on viral influenza were clinically observed, and 100 out of outpatient adult patients were clearly diagnosed as having mild, moderate and severe viral influenza, and were divided into a treatment group and a control group, respectively, and the patients with mild, moderate and severe influenza were equally distributed.
Treatment group 1: wherein 20 patients are treated by the traditional Chinese medicine composition of the embodiment 1, and the traditional Chinese medicine composition is taken 2 times a day, 10ml each time, on an empty stomach in the morning and evening; treatment effect data were collected 4 days after treatment.
Treatment group 2: wherein 20 patients are treated by the traditional Chinese medicine composition of the embodiment 2, and the composition is taken 2 times a day in the morning and evening on an empty stomach, 2 granules for each time; treatment effect data were collected 4 days after treatment.
Treatment group 3: wherein 20 patients are treated by the traditional Chinese medicine composition of the embodiment 3, and the composition is taken 2 times a day, on an empty stomach in the morning and evening, 2 bags each time; treatment effect data were collected 4 days after treatment.
Treatment group 4: wherein 20 patients are treated by the traditional Chinese medicine composition of the embodiment 4, and the composition is taken 2 times a day in the morning and evening on an empty stomach, 2 tablets each time; treatment effect data were collected 4 days after treatment.
Control group: the other 20 patients are treated by using the traditional Chinese medicine antiviral capsules produced by a certain pharmaceutical factory on the market, and are taken 2 times a day, 2 capsules each time in the morning and evening on an empty stomach; treatment effect data were collected 4 days after treatment.
The treatment results data for the treated and control groups after the treatment period are shown in table 1.
Table 1 comparative treatment results table
| Distinguishing | Can completely cure the disease | Obviously improve | The effect is not obvious | Without significant improvement |
| Treatment group 1 | 95% | 10% | 0% | 0% |
| Treatment group 2 | 92% | 8% | 0% | 0% |
| Treatment group 3 | 90% | 7% | 0% | 0% |
| Treatment group 4 | 94% | 9% | 0% | 0% |
| Control group | 65% | 6% | 10% | 5% |
Typical cases
1. In a male, age 36, the diagnosis of viral cold is confirmed, and the clinical manifestations are: the symptoms of low fever, anorexia, nausea, emesis, etc. can be repeatedly attacked for 4 times, and the clinical symptoms can be improved after taking the Chinese medicinal composition prepared by the first preparation for 3 days, and no recurrence can be observed after tracking for 1 month.
2. Some young, female, 22 years old, has confirmed the diagnosis of viral cold, with the clinical manifestations: the symptoms of low fever, hypodynamia, nausea, vomiting and the like repeatedly attack for 2 times, the clinical symptoms are obviously improved after the traditional Chinese medicine composition prepared in the second administration example is taken for 4 days, and the clinical symptoms are improved after the traditional Chinese medicine composition is continuously taken for the third day and are tracked for 1 month without relapse.
3. When a man is in age of 45 years, the disease is diagnosed as a viral cold, and the clinical manifestations are as follows: the symptoms of low fever, hypodynamia, nausea, vomiting and the like repeatedly attack for 2 times, the clinical symptoms are obviously improved after the traditional Chinese medicine composition prepared in the third example is taken for 2 days, and the clinical symptoms are improved after the traditional Chinese medicine composition is continuously taken for the fifth day and are tracked for 1 month without relapse.
4. Xuan somebody, male, 56 years old, confirmed to be a viral cold, with clinical manifestations: the symptoms of low fever, hypodynamia, nausea, vomiting and the like repeatedly attack for 2 times, and the clinical symptoms are obviously improved after taking the traditional Chinese medicine composition prepared in the third embodiment for 4 days, and the relapse is not seen after tracking for 1 month.
In view of the process of infecting the epithelium of human lung vacuoles, viruses firstly utilize the Spike protein of the virus to interact with ACE2 protein, so as to invade the human body. The interface inhibitor aiming at the interaction of the Spike and the ACE2 protein is developed, so that the combination of the two proteins can be effectively cut off, the virus is blocked from invading human cells, and the effect of preventing infection is achieved. Aiming at the research and development of a virus Spike protein/ACE 2 interaction interface inhibitor, particularly effective molecules are screened from medicine-food homologous molecules, hot spots and key residues of a protein-protein interaction interface of a 2019_ nCov virus CTD 1/human ACE2 compound are clarified by comparing the combination mode of SARS virus Spike protein/human ACE2 protein, a pharmacophore model is constructed by ACE2 amino acid residues by utilizing a structure-based pharmacophore method, the surface of a CTD1 region combined with ACE2 is targeted, candidate inhibitors are screened, and the recognition and combination of viruses and human ACE2 protein are blocked. Finally, through a constructed pharmacophore model and a molecular docking screening method, 13 traditional Chinese medicines of potential inhibitors of the targeted S protein are screened from a patent medicine compound library (2373 compounds) and a medicine and food homology source database (5632 compounds), wherein 4 medicines (astragalus, honeysuckle, platycodon grandiflorum and dried ginger) are contained in the invention.
Through the technical scheme, the invention provides a traditional Chinese medicine prescription for preventing virus infection, which is supported by an oral liquid preparation through the proportion of five traditional Chinese medicines. The oral preparation has effects of strengthening body resistance, consolidating constitution, eliminating turbid pathogen, and removing toxic substance, and also has spleen invigorating effect. All the medicinal materials are medicinal and edible traditional Chinese medicines, are safe and reliable, and are suitable for the public to prevent the infection of influenza virus and coronavirus.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (5)
1. A traditional Chinese medicine prescription for preventing virus infection is characterized by comprising the following traditional Chinese medicines in parts by weight: 20 parts of astragalus membranaceus, 5 parts of honeysuckle, 5 parts of platycodon grandiflorum, 6 parts of dried orange peel and 2 parts of dried ginger.
2. The Chinese medicinal formulation for preventing viral infection according to claim 1, wherein the Chinese medicinal formulation is an oral liquid formulation.
3. The Chinese medicinal formulation for preventing viral infection according to claim 1, wherein the Chinese medicinal formulation is a capsule formulation.
4. The Chinese medicinal formulation for preventing viral infection according to claim 1, wherein the Chinese medicinal formulation is a tablet.
5. The Chinese medicinal formulation for preventing viral infection according to claim 1, wherein the Chinese medicinal formulation is a granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010117903.3A CN111184854A (en) | 2020-02-26 | 2020-02-26 | Chinese medicinal prescription for preventing virus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010117903.3A CN111184854A (en) | 2020-02-26 | 2020-02-26 | Chinese medicinal prescription for preventing virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111184854A true CN111184854A (en) | 2020-05-22 |
Family
ID=70687541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010117903.3A Withdrawn CN111184854A (en) | 2020-02-26 | 2020-02-26 | Chinese medicinal prescription for preventing virus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111184854A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617342A (en) * | 2023-01-18 | 2023-08-22 | 渤海大学 | A kind of preparation method of atomized spray for Omicron virus infection |
| WO2024153266A1 (en) * | 2023-01-20 | 2024-07-25 | 广东省中医院 | Medicated diet composition for treating cold cough, and preparation method therefor and use thereof |
-
2020
- 2020-02-26 CN CN202010117903.3A patent/CN111184854A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617342A (en) * | 2023-01-18 | 2023-08-22 | 渤海大学 | A kind of preparation method of atomized spray for Omicron virus infection |
| WO2024153266A1 (en) * | 2023-01-20 | 2024-07-25 | 广东省中医院 | Medicated diet composition for treating cold cough, and preparation method therefor and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111671880B (en) | Traditional Chinese medicine preparation for treating fever caused by coronavirus pneumonia | |
| KR20220098360A (en) | Forsythia-Astragalus peritoneal preparation and its manufacturing method and use | |
| CN103169891A (en) | Novel vitamin C yinqiao tablet | |
| CN103585514A (en) | Traditional Chinese medicine composition for treating stomach cancer, application and preparation | |
| AU2024205781A1 (en) | Combined plant compounds for use in the treatment of viral infections including covid-19 | |
| CN101327295B (en) | Chinese medicine for releasing toxicity and relieving inflammation | |
| CN111184854A (en) | Chinese medicinal prescription for preventing virus infection | |
| CN110193061A (en) | A kind of preparation and application of the Chinese herbal granules treating or preventing influenza virus of children infection | |
| CN103041030B (en) | Pharmaceutical composition for treating fever with swollen head, as well as preparation method and application thereof | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN102988851A (en) | Chinese medicine composition for treating hemoptysis and preparation method of Chinese medicine composition | |
| CN116236550A (en) | Light traditional Chinese medicine formula preparation for treating novel coronavirus infection and preparation method thereof | |
| CN101606960B (en) | Oral medicinal composition | |
| CN1329047C (en) | Chinese medicinal composition for treating acute icterohepatitis | |
| CN101485844B (en) | Chinese medicinal composition for treating chronic gastritis | |
| CN105796746B (en) | Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection | |
| CN109453247A (en) | A kind of prevention and treatment four seasons common cold, influenza, the Chinese medicine composition of bird flu, Chinese medical extract and preparation method thereof and dosage form | |
| CN111544466B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for preventing neocoronary pneumonia | |
| CN100409884C (en) | Chinese traditional medicine for treating cold | |
| CN104189610A (en) | Traditional Chinese medicine composition for treating bronchitis | |
| CN104887863A (en) | Lingual tonsilitis treatment traditional Chinese medicine spray and preparation method thereof | |
| CN103156960B (en) | A kind of Chinese medicine composition for the treatment of acquired immune deficiency syndrome (AIDS) | |
| CN103520632B (en) | One is used for the treatment of grippal Chinese medicine composition and preparation method thereof | |
| CN118717901A (en) | A Chinese medicine composition and a drug preparation for dispelling exterior pathogens and clearing interior pathogens | |
| CN104127631A (en) | Traditional Chinese medicinal composition for treating tinea cruris and tinea inguinalis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200522 |
|
| WW01 | Invention patent application withdrawn after publication |